Understand the source comparison
Cardiogen vs Other Cardiovascular Peptides
If you are weighing Cardiogen against other options, a side-by-side helps. None of these peptides is FDA-approved for cardiac use, and the evidence quality varies a lot. Cardiogen vs TB-500 (thymosin beta-4). TB-500 is a much longer peptide (43 amino acids) wi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- If you are weighing Cardiogen against other options, a side-by-side helps. None of these peptides is FDA-approved for cardiac use, and the evidence quality varies a lot.
- Cardiogen vs TB-500 (thymosin beta-4). TB-500 is a much longer peptide (43 amino acids) with substantial Western research on heart repair after ischemia, including animal data on heart-cell migration and new blood vessel growth (Bock-Marquette et al., 2004). TB-500 has a stronger mechanistic evidence base than Cardiogen, but it has the same regulatory status: no FDA approval for cardiac indications. See what does TB-500 do for a full profile.
- Cardiogen vs BPC-157. BPC-157 is mainly a gut and musculoskeletal repair peptide, but a handful of rat studies suggest cardioprotective effects in arrhythmia models. Its evidence base is similar in size to Cardiogen's, but it is concentrated in Croatian rather than Russian labs. BPC-157 is currently attracting more replication interest in Western labs. See BPC-157 vs TB-500.
- Cardiogen vs thymosin alpha-1. Thymosin alpha-1 is an immune peptide with some evidence in viral cardiomyopathy. It is not primarily a cardiac compound. The two peptides come from different classes and Russian clinicians sometimes stack them. See thymosin alpha-1 benefits.
- Cardiogen vs conventional cardiac drugs. This is not a real comparison. Statins, beta blockers, ACE inhibitors, and dual antiplatelet therapy have decades of randomized trial evidence with hundreds of thousands of participants behind them. Cardiogen has a few hundred patients in small open-label studies. If you have known coronary disease, you do not substitute Cardiogen for the proven drug. You add it on top, with your cardiologist's input, or you skip it.
- Where Cardiogen fits in a stack (if you decide to use it). Russian protocols use it alongside conventional medication for aging-related cardiac support, not as a replacement. It is sometimes cycled with peptides aimed at the pineal gland and the thymus on the theory that all three systems age together. These stacks do not have randomized trial evidence and you should treat them as experiments. For checking interactions before stacking, see the peptide interaction checker.